Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

Clin Infect Dis

Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University of Zurich, Switzerland.

Published: December 2014

Progressive multifocal leukoencephalopathy is a currently untreatable infection of the brain. Here, we demonstrate in 2 patients that treatment with interleukin 7, JC polyomavirus (JCV) capsid protein VP1, and a Toll-like receptor 7 agonist used as adjuvant, was well tolerated, and showed a very favorable safety profile and unexpected efficacy that warrant further investigation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650775PMC
http://dx.doi.org/10.1093/cid/ciu682DOI Listing

Publication Analysis

Top Keywords

progressive multifocal
8
multifocal leukoencephalopathy
8
capsid protein
8
protein vp1
8
treating progressive
4
leukoencephalopathy interleukin
4
interleukin vaccination
4
vaccination virus
4
virus capsid
4
vp1 progressive
4

Similar Publications

Fall rates in bifocal, trifocal, and progressive addition lens glasses wearers.

Optom Vis Sci

January 2025

Department of Aged Care and Rehabilitation, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Purpose: There is evidence that wearing multifocal glasses increases the risk of falls in older people, especially when walking on stairs and in unfamiliar settings. However, it is not clear whether all types of multifocal glasses are equally associated with falls. This study comprised a secondary analysis of data from the VISIBLE randomized controlled trial to determine whether fall rates differ among older bifocal, trifocal, and progressive addition lens glasses wearers.

View Article and Find Full Text PDF

A 78-years-old man was treated for asthma and pansinusitis for >5 years, and mepolizumab was initiated two years previously. Two months after the cessation of mepolizumab treatment, the asthma symptoms worsened and acute progressive muscle weakness and sensory disturbance developed. On day 8 after the onset of weakness and hypoesthesia, the patient presented with complete flaccid tetraplegia and diffuse hypoesthesia of all extremities, without paresthesia or pain, and was admitted to our hospital.

View Article and Find Full Text PDF

Glioblastoma (GBM) classification involves a combination of histological and molecular signatures including IDH1/2 mutation, TERT promoter mutation, and EGFR amplification. Non-canonical mutations such as BRAF, found in 1-2% of GBMs, activate the MEK-ERK signaling pathway. This mutation can be targeted by small molecule inhibitors, offering therapeutic potential for GBM.

View Article and Find Full Text PDF

The longest reported follow-up for thermal ablation of papillary thyroid microcarcinoma (PTMC) is 5 years. We evaluated the long-term efficacy and safety of radiofrequency ablation (RFA) in patients with low-risk PTMC with clinical follow-up of more than 10 years. In this retrospective cohort study, we included patients with low-risk PTMC who had more than 10 years of follow-up after ultrasound (US)-guided RFA (performed between May 2008 and December 2013).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!